Our FDA-Approved CAR-T Cell Therapy
With the discovery of the first gene therapy to be approved by the FDA, Penn Medicine is leading the world in immunotherapy research. Our researchers are working relentlessly to realize the full potential of this innovative approach: reprogramming the body’s own immune cells to seek and destroy every last cancer cell.
One way that we’re doing this is through an immunotherapy treatment option called CAR-T cell therapy. A personalized cellular therapy, it teaches the body’s immune systems to recognize and kill cancer cells.
CAR-T cell therapy has become a powerful addition to Penn’s cancer-fighting arsenal of surgery, targeted therapies, and precision radiation treatments. We have treated nearly 500 blood cancer patients in CAR-T clinical trials.
For more information, call 215-316-5127 or request a call-back today.
Additional Cutting-Edge Immunotherapy Treatments at Penn
Our dynamic research program is always growing. In addition to CAR-T cell therapy, we focus on other types of immunotherapy research, such as vaccine therapy and checkpoint inhibitors.
Interview with CAR-T Pioneer, Dr. June
Carl June, MD, is one of the pioneers of immunotherapy research, and he leads the team responsible for the historic CAR-T cell therapy FDA approval. Listen to him discuss the journey that led to the first FDA approval of CAR-T cell therapy and how he believes cancer will be treated in the future.
Donate to Support Immunotherapy Research
Our success with CAR-T cell therapy is all thanks to the help we’ve received from our partners, researchers, philanthropists, and fellow cancer visionaries. Donate today, so we can continue creating immunotherapy treatments to put more and more people in remission.